Loading data for PHAT — first visit, this takes a few seconds.

알림

Phathom Pharmaceuticals I... (PHAT)

NasdaqGS: PHAT · 실시간 가격 · USD

9.65

+0.40 (4.32%)

종가 기준: Aug 19, 2026, 2:00 PM

4.32% (1D)

데이터 없음

매수호가	6.84
시가총액	781.1M
매출 (ttm)	239.66M
순이익 (ttm)	-99.07M
베타	0.50
EPS (ttm)	-1.25
P/E (ttm)	n/a
선행 P/E	8.7
P/B (ttm)	-2.25
P/S (ttm)	3.26
Earnings Date	Jul 30, 2026

매도호가	12.28
거래량	86,169
평균 거래량 (20일)	1,321,293
시가	9.42
전일 종가	9.25
일중 범위	9.42 - 9.70
52주 범위	8.21 - 18.31
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

PHAT 소개

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacte...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 25, 2019

직원 수 371

상장 거래소 NasdaqGS

티커 PHAT

웹사이트 https://www.phathompharma.com

전체 기업 정보

재무 실적

2025년 Phathom Pharmaceuticals의 매출은 175.11M로, 전년 55.25M 대비 216.93% 증가했습니다. 순이익은 -221.25M로, -33.82% 감소했습니다.

재무제표

어닝 서프라이즈

Phathom Pharmaceuticals가 Apr 30, 2026에 분기 실적을 발표했습니다:

매출 $74.27M 예상치 하회 $0, 및 88.02% 전년 대비 성장.

EPS -0.18 예상치 상회 0.01, 및 83.18% 전년 대비 성장.

다음 실적 발표

Phathom Pharmaceuticals Inc.의 실적 발표 예정일은 Jul 30, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3일 전 · Simply Wall St.

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

The latest update on Phathom Pharmaceuticals centers on a reset in valuation anchors, with fair value moving from US$23.70 to US$21.50 as analysts revisit their price targets. This change reflects a m...

2주 전 · Stocktwits

PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?

Phathom lowered its full-year 2026 net revenue outlook to $310–325 million from the prior $320–345 million range.

2주 전 · MarketBeat

Phathom Pharmaceuticals Q2 Earnings Call Highlights

Phathom Pharmaceuticals (NASDAQ:PHAT) reported second-quarter 2026 revenue growth of 88% year over year and said it achieved positive operating profit excluding stock-based compensation for the first ...

2주 전 · GuruFocus.com

Phathom Pharmaceuticals Inc (PHAT) (Q2 2026) Earnings Call Highlights: First Positive Operating ...

Phathom Pharmaceuticals Inc (PHAT) achieves milestone profitability and strong revenue growth, but faces physician friction in the prior authorization process for Voquezna.

2주 전 · Zacks

Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of +100.00% and +1.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

2 페이지 중 1